Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

HYDERABAD, India, January 21 /PRNewswire/ --

- FY2008 Revenue Now Estimated at US$2.1 Billion

Satyam Computer Services Ltd. (NYSE:SAY), a leading business and information technology services provider, today announced the results of the company for the quarter ended December 31, 2007 (Q3).

Consolidated Indian GAAP Highlights

- Revenue was Rs. 2195.56 crore; a year-over-year increase of 32.2% and a sequential increase of 8.1%.

- Volume growth for the quarter was 9.4%.

- Net Profit after Tax was Rs. 433.63 crore; a year-over-year increase of 28.6% and a sequential increase of 6%.

- EPS was Rs. 6.48; a Year-over-year increase of 26.1% and a sequential increase of 5.9%.

- EBITDA margin for the quarter was 21.46%.

HYDERABAD, India, January 21 /PRNewswire/ --

- Chicago-Based Management Consulting Firm Strengthens Company's High-End Business Services

Satyam Computer Services Ltd. (NYSE:SAY), a leading business and information technology services provider, today announced that it has entered into a definitive agreement to acquire Bridge Strategy Group, a Chicago, Ill.-based management consulting firm. In making the $35 million, all-cash purchase, Satyam significantly reinforces its strategy consulting and business transformation capabilities.

HOLLYWOOD, California, January 21 /PRNewswire/ --

YouTube phenomenon Alisa Apps gets censored again. In only three weeks since the launch of her music career, Alisa has taken the YouTube music world by storm.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080121/LAM037)

Now with her new video, "The Protector," an amazing Lynch, Hitchcock like piece, Alisa Apps got 50,000+ views in only 8 hours and was once again, #1 in the UK music charts and #3 in the world. This video has now been flagged. Her previous music video "Confusion" was also flagged and then taken down! (Link to Alisa's censored video: http://www.youtube.com/watch?v=aSRzCFIejGc)

ZUG, Switzerland, January 21 /PRNewswire/ -- Swiss Hawk AG is proud to announce that overall the Company's seven investment portfolio participations performed very well during 2007 and are on course for significant growth in value during 2008.

The company expects to start a disposal from its holdings in quoted companies from March 2008 and onwards.

It is expected that all unquoted investment holdings will be quoted on a recognised stock exchange or will be disposed through trade sales during the coming three months. At the time of listing of the unquoted companies a disposal plan will be agreed on.

It is the Company's policy to make investments only when a short term Exit plan is in place, with Exit timeframe being approximately 12 months.

COPENHAGEN, January 21 /PRNewswire/ --

- Summary: Genmab has Achieved two Development Milestones in its Ofatumumab Collaboration with GlaxoSmithKline

Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK).

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007. The third milestone payment of DKK 87.2 million was triggered by the first patient receiving treatment in the Phase III rheumatoid arthritis (RA) program, which occurred in 2008.

LOS ANGELES, January 21 /PRNewswire/ --

- Following FDA Approval, Company Announces US$7,800 Wholesale Price for Lifesaving Drug